E-SOLVE 2
Clinical safety rating: caution
Comprehensive clinical and safety monograph for E-SOLVE 2 (E-SOLVE 2).
E-SOLVE 2 is a monoclonal antibody that binds to and inhibits the activity of proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9-mediated degradation of low-density lipoprotein receptors (LDLR) on hepatocytes, thereby increasing hepatic uptake of LDL cholesterol and reducing plasma LDL-C levels.
| Metabolism | E-SOLVE 2 is a monoclonal antibody, degraded by general protein catabolism via reticuloendothelial system; not metabolized by cytochrome P450 enzymes. |
| Excretion | E-SOLVE 2 is eliminated primarily via renal excretion (approximately 70% of the dose as unchanged drug) and biliary/fecal excretion (approximately 30%, with some metabolites). |
| Half-life | The terminal elimination half-life is 12-16 hours, allowing for once-daily dosing. Accumulation may occur in renal impairment. |
| Protein binding | Approximately 85-90% bound primarily to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 24 hours (supports once-daily dosing); Intravenous: 12-24 hours depending on dose. |
| Molecular Weight | 512.6 |
2 tablets (each containing ezetimibe 10 mg and simvastatin 20 mg) orally once daily in the evening, with or without food. Maximum daily dose: ezetimibe 10 mg/simvastatin 80 mg.
| Dosage form | LOTION |
| Renal impairment | If GFR < 30 mL/min/1.73 m², use ezetimibe 10 mg/simvastatin 10 mg once daily. For GFR 30-80 mL/min/1.73 m², no adjustment required. Avoid simvastatin doses >20 mg in patients with severe renal impairment. |
| Liver impairment | Contraindicated in active liver disease or unexplained persistent transaminase elevations. In Child-Pugh Class A or B, no dose adjustment; use with caution. In Child-Pugh Class C, not recommended (no data). |
| Pediatric use | For children 10-17 years with heterozygous familial hypercholesterolemia: ezetimibe 10 mg/simvastatin 10 mg to 40 mg orally once daily in the evening. Dose based on baseline LDL-C and response, titrated at 4-week intervals. Maximum simvastatin dose 40 mg daily. |
| Geriatric use | No specific dose adjustment required for age >65 years. Use lowest effective simvastatin dose due to increased risk of myopathy (e.g., start at 10 mg simvastatin). Monitor renal function and muscle symptoms. |
| 1st trimester | Avoid; potential teratogenicity (limited human data, animal studies show risk). |
| 2nd trimester | Use only if benefit outweighs risk; may affect fetal growth. |
| 3rd trimester | Avoid near term due to risk of premature closure of ductus arteriosus. |
Clinical note
Comprehensive clinical and safety monograph for E-SOLVE 2 (E-SOLVE 2).
| Placental transfer | Crosses placenta; detected in fetal circulation at maternal levels. |
| Breastfeeding | Excreted in breast milk; insufficient data to recommend use during breastfeeding. Consider benefits versus potential infant exposure. |
| Lactation Rating |
■ FDA Black Box Warning
None (no FDA black box warning)
| Serious Effects |
Severe hepatic impairmentHypersensitivity to drug or excipientsConcomitant use with MAOIs
| Precautions | Allergic reactions including angioedema and urticaria have been reported; discontinue if serious hypersensitivity occurs, May increase risk of injection site reactions (e.g., erythema, pain, bruising), Risk of immune-mediated adverse events (e.g., serum sickness) with chronic use, Not studied in patients with severe hepatic impairment; use with caution if hepatic disease present |
| Food/Dietary | Avoid grapefruit juice and grapefruit products as they increase statin levels and risk of adverse effects. Limit alcohol intake to ≤2 drinks/day to reduce hepatotoxicity risk. Avoid high-fat meals immediately before dosing to maximize absorption; take without regard to meals. |
Loading safety data…
| L3 (Moderately Safe) or Avoid |
| Teratogenic Risk | First trimester: Crosses placenta; animal studies show embryotoxicity at supratherapeutic doses; human data insufficient to exclude risk. Second/third trimester: No specific malformations reported; potential for fetal growth restriction due to maternal hemodynamic effects. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and renal function. Evaluate fetal growth via ultrasound every 4-6 weeks from 28 weeks gestation. Assess amniotic fluid volume and umbilical artery Doppler if preeclampsia suspected. |
| Fertility Effects | No known adverse effects on fertility in preclinical studies. In humans, no specific data; theoretical potential for hormonal interference (based on mechanism of action) warrants counseling for patients planning conception. |
| Clinical Pearls | E-SOLVE 2 is a high-potency statin (rosuvastatin 40 mg equivalent) requiring baseline and periodic liver function tests; avoid in active liver disease. Monitor for myopathy, especially in patients with renal impairment or on interacting drugs like gemfibrozil. Dose adjustment needed for eGFR <30 mL/min. Advise against excessive alcohol consumption. |
| Patient Advice | Take exactly as prescribed, usually once daily at the same time. · Report unexplained muscle pain, tenderness, or weakness immediately. · Avoid grapefruit juice and grapefruit products. · Do not take with red yeast rice or other statin-containing supplements. · If you miss a dose, skip it; do not double the next dose. · Maintain a heart-healthy diet low in saturated fats and cholesterol. · Inform all healthcare providers you are taking this medication. |